UPPSALA, Sweden

Otte Marthin

This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignee: Raysearch Laboratories Ab (Publ). Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Otte Marthin: Innovator in Ion Radiotherapy Optimization

Introduction

Otte Marthin is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of ion radiotherapy through his innovative methods and technologies. His work focuses on optimizing treatment planning for patients undergoing radiotherapy.

Latest Patents

Otte Marthin holds a patent for a method of ion PBS treatment optimization, which includes a computer program product and a computer system designed to perform the method. This computer-based method provides a set of selected spots for use in ion radiotherapy optimization. The process involves defining positions in a volume that correspond to potential Bragg peak locations, performing ray tracing to determine characteristics of potential spots, and selecting the most suitable spots for treatment planning. This invention enhances the precision and effectiveness of radiotherapy treatments.

Career Highlights

Otte Marthin is associated with Raysearch Laboratories AB, a company known for its advancements in radiation therapy software. His work at the company has been instrumental in developing innovative solutions that improve patient outcomes in cancer treatment.

Collaborations

Otte has collaborated with esteemed colleagues such as Lars Glimelius and Erik Engwall, contributing to the advancement of technology in the field of radiotherapy.

Conclusion

Otte Marthin's contributions to ion radiotherapy optimization exemplify the impact of innovative thinking in medical technology. His patent and work at Raysearch Laboratories AB highlight the importance of precision in cancer treatment.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…